Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials.
D ThaçiDenis JullienAlexander EgebergY José Manuel CarrascosaJ J WuI Pau-CharlesPaolo GisondiPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)